At present, no standard manufacturing guideline exists for depositing hydro
xyapatite (HA) on implant surfaces. Although animal and in vitro studies ha
ve reported on the benefits of using HA-coated implants as well as the risk
s of dissolution, these short-term studies did not demonstrate that the dis
solution of the HA coating leads to a loss of implants. In addition, many i
n vivo and clinical studies did not include the chemical and structural cha
racterization of the coatings, and thus comparisons between studies are dif
ficult.
In the clinics, the recommendation is that HA-coated screw implants be used
for the anterior maxilla and posterior mandible where the bone depth excee
ds 10 mm and when the cortical layer is thinner and spongiosia is less dens
e. In the posterior maxilla or when the cortical layer is very thin with lo
w density, the use of HA-coated cylindrical implants is recommended. Howeve
r, there are concerns for using IIA-coated implants. The clinician needs to
take into consideration the enhanced bacterial susceptibility of IIA coati
ngs compared with titanium implants. In addition, the clinician needs to co
nsider the possible failure of FIA coatings as a result of coating-substrat
e interfacial fracture. Finally, besides the surgical skills, it is also im
portant that the clinical investigators be well versed with the materials c
haracterization needed for HA-coated implants, the problems associated with
the current HA coatings, and the indications for use. In addition, the cor
relation between well characterized coatings and their effect on bone forma
tion rate and long-term implant success, coating-implant interfacial streng
th, and alternative superior coating process need to be investigated furthe
r.